Our Approach

The next generation in immunotherapy

Antibody therapies have transformed the therapeutic landscape for a wide variety of diseases, from cancer to COVID-19. However, traditional IgG antibodies are limited due to their large size (~150 kDa), chemical instability, manufacturing cost, and humanization step requirements.[1-2] Additionally, it is extremely challenging to engage multiple targets with traditional antibodies.

Image adapted from Yang EY, Shah K. Front Oncol 2020. doi: 10.3389/fonc.2020.01182. Licensed under CC BY.

VINCOBODIES are fragments of antibodies that consist of a single monomeric variable domain.[3] Compared to traditional antibodies, VINCOBODIES offer several advantages:

  • Selective targeting of cytokines, unleashing the body’s natural immune response

  • Deeper tissue penetration

  • Stable at 90ºC and a wide range of pHs

  • No humanization step requirement

  • Lower manufacturing costs due to high yield and concentration

  • Ability to reach multiple targets with high avidity using a single scaffold

Vicero’s Novel Technology Platform

We are disrupting the immunotherapy space by engaging bi- and tri-specific targets with a single VINCOBODY scaffold. Our novel platform provides the flexibility to quickly move into therapeutic combinations and adjust in-flight in a rapidly evolving competitive landscape.

Customized delivery systems for life-changing therapies

Our customized delivery systems for different indications enhance safety and reduce risk—without the need for new molecules.

  • Bi- and tri-specific VINCOBODIES can selectively target multiple mechanisms of action, synergizing to improve the therapeutic index and maximize clinical benefit

  • Cytosolic, membrane-bound, or secreted proteins can be targeted depending on indication

  • Rich pipeline of bi-specific VINCOBODIES enables rapid adoption of combination strategy during clinical development

  1. Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603. doi: 10.3389/fimmu.2017.01603.
  2. Sun S, Ding Z, Yang X, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomedicine. 2021;16:2337-56. doi: 10.2147/IJN.S297631
  3. Mir MA, Mehraj U, Sheikh BA, Hamdani SS. Nanobodies: The “Magic Bullets” in therapeutics, drug delivery and diagnostics. Hum Antibodies. 2020;28(1):29-51. doi: 10.3233/HAB-190390.